5 completed. 5 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 5 |
| Phase 3 | 1 | Completed 1 |
Follow Shingles: new trials by email Literature Review of Shingles trials Research Report on Shingles
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Systems Biology of Zoster Vaccine Shingrix® - Zoster, Zoster Varicella | Phase 2 | Completed | Emory University | 38 | 2019-11-14 | 2024-07-30 |
| A Study of FV-100 Versus Valacyclovir in Patients With Herpes Zoster valacyclovir, FV-100, Valacyclovir placebo - Herpes Zoster, Shingles | Phase 2 | Completed | Bristol-Myers Squibb | 350 | 2009-05-01 | 2015-10-12 |
| A 2 Week Study of Topical KD7040 in the Treatment of Postherpetic Neuralgia (PHN) KD7040 Topical Gel, Placebo gel - Postherpetic Neuralgia, Shingles | Phase 2 | Completed | Kalypsys, Inc. | 48 | 2007-11-01 | 2008-07-22 |
| Safety, Tolerability, and the Body's Ability to Develop Resistance to an Investigational Vaccine for Shingles (V211-007) zoster vaccine live (Oka/Merck), Comparator: placebo (unspecified) - Shingles | Phase 2 | Completed | Merck Sharp & Dohme LLC | 180 | 2001-11-01 | 2017-03-15 |
| NGX-4010 for the Treatment of Postherpetic Neuralgia Capsaicin Dermal Patch - Herpes Zoster, Neuralgia | Phase 2 / Phase 3 | Completed | NeurogesX | 300 | 2008-03-06 |
Herpes Zoster (5) · Neuralgia (2) · Chickenpox (1) · Neuralgia, Postherpetic (1) · Pain (1) · Peripheral Nervous System Diseases (1)
DNA Virus Infections (5) · Herpesviridae Infections (5) · Infections (5) · Varicella Zoster Virus Infection (5) · Virus Diseases (5) · Nervous System Diseases (2) · Neurologic Manifestations (2) · Neuromuscular Diseases (2) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · Pain (1) · Peripheral Nervous System Diseases (1)
FV-100 (1) · Herpes Zoster Vaccine (1) · Valacyclovir (1)
Bristol-Myers Squibb (1) · Emory University (1) · Kalypsys, Inc. (1) · Merck Sharp & Dohme LLC (1) · NeurogesX (1)
United States (3)
U19AI090023 (1)